Pharm-Olam International, a Houston-based, multinational, full-service CRO, is relocating its Polish location to a larger office to accommodate a growing staff.
“We have seen a significant increase in interest in running trials in Poland and we are expanding our offices to accommodate the current and future workload,” said Sanjiv Suri, U.S. chief executive officer. “When we opened our first operating office in Poland in 1995, we had to convince potential sponsors to place their trials in this emerging country. Nowadays, Poland is near the top of the list of countries that sponsors know can produce high-quality data, on time. Our staff numbers in Poland has increased over the past few years and we anticipate a 25% growth of our staff in Poland to meet upcoming demand.”
Pharm-Olam’s Poland Country Manager Dr. Janusz Rupinski said, “With a population of almost 40 million people, Poland offers rapid recruitment in most therapeutic areas. When combining the extensive population with experienced investigational staff and the efficient transfer of study supplies as an E.U. member state, Poland is primed for extensive growth in the clinical trial arena. As of Sept. 22, 2015, there were approximately 1,150 phase I-IV active clinical trials ongoing in Poland. Of these trials, there were 396 trials registered in 2014 and 329 in 2015 to date.”